美国某医疗系统中铁缺乏的缓解率及缓解时间
该回顾性研究纳入美国明尼苏达州某医疗系统2010至2020年13084例铁缺乏(铁蛋白≤25 ng/mL)患者,41.9%在诊断后3年内铁蛋白恢复至≥50 ng/mL,中位缓解时间1.9年;年龄≥60岁、男性及静脉铁治疗与更可能缓解相关,黑人种族与较低缓解可能性相关。
要点
- 13084例铁缺乏患者中41.9%在3年内缓解,58.1%无缓解记录。
- 中位缓解时间1.9年(四分位距0.8-3.9年)。
- 女性及黑人个体缓解可能性较低,静脉铁治疗者缓解可能性较高。
核心结论
- 铁缺乏持续存在比例高且总体缓解时间长,女性和黑人个体无缓解风险更高,需要有针对性的知识转化干预以促进及时诊断和确定性治疗。
研究设计与样本
- 回顾性电子病历数据研究,来自美国明尼苏达州某全州医疗系统,纳入2010至2020年铁蛋白≤25 ng/mL且3年内至少有一次随访铁蛋白的铁缺乏患者13084例。
主要发现
- 5485例(41.9%)在诊断后3年内铁蛋白恢复至≥50 ng/mL,7599例(58.1%)无缓解记录。
- 中位缓解时间为1.9年(四分位距0.8-3.9年)。
- 年龄≥60岁与更可能缓解相关(校正风险比[aHR] 1.56;95%置信区间[CI] 1.44-1.69)。
- 男性与更可能缓解相关(aHR 1.58;95% CI 1.48-1.70),静脉铁治疗与更可能缓解相关(aHR 2.96;95% CI 2.66-3.30)。
- 黑人种族与较低缓解可能性相关(aHR 0.73;95% CI 0.66-0.80)。
关键数值与推荐
- 铁缺乏定义为铁蛋白≤25 ng/mL。
- 铁缺乏缓解定义为后续铁蛋白≥50 ng/mL。
临床怎么用
- 作者认为需要有针对性知识转化干预以促进该常见可纠正疾病的及时诊断和确定性治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron deficiency (ID) is a global health problem with consequences independent of anemia, including impaired cognition and exercise tolerance. The time from laboratory diagnosis to resolution of ID has not been defined. In a retrospective review of electronic medical record data from a Minnesota statewide health system, we identified patients with ID (ferritin level ≤25 ng/mL). Patients with at least 1 follow-up ferritin level within 3 years were included. Patients with a subsequent ferritin of ≥50 ng/mL were classified as having resolved ID. Descriptive statistics and time-to-event analyses were used to determine proportion of ID resolution and time to resolution, and to evaluate characteristics predictive of resolution. We identified 13 084 patients with ID between 2010 to 2020. We found that 5485 (41.9%) had resolution within 3 years of diagnosis, whereas 7599 (58.1%) had no documented resolution. The median time to resolution was 1.9 years (interquartile range, 0.8-3.9). Factors associated with greater likelihood of resolution included age of ≥60 years (adjusted hazard ratio [aHR], 1.56; 95% confidence interval [CI], 1.44-1.69]), male sex (aHR, 1.58; 95% CI, 1.48-1.70]) and treatment with intravenous iron (aHR, 2.96; 95% CI, 2.66-3.30). Black race was associated with a lower likelihood of resolution (aHR, 0.73; 95% CI, 0.66-0.80). We observed a high proportion of persistent ID and prolonged time to resolution overall, with greater risk of lack of resolution among females and Black individuals. Targeted knowledge translation interventions are required to facilitate prompt diagnosis and definitive treatment of this prevalent and correctable condition.
引用
- Cogan JC, Meyer J, Jiang Z, et al. Iron deficiency resolution and time to resolution in an American health system. Blood Adv. 2024. PMID: 39145727. doi:10.1182/bloodadvances.2024013197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。